Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 1 of 33 · 1579 articles
Subtopics
The study suggests a natural seaweed-derived polysaccharide could modify gut bacteria and immune signaling in ways that reduced experimental colitis, which may interest people looking for microbiota-targeted dietary...
This preclinical study suggests a traditional medicinal plant extract may reduce inflammation and tissue damage in an experimental model of ulcerative colitis, which could guide future drug-discovery research relevant to...
This method helps translate complex paired microbiome and metabolome data into coherent functional modules; that could clarify microbial metabolic alterations in IBD or IBS and guide future biomarker or mechanistic...
The study suggests a dietary/prebiotic compound (2'-FL) can change gut microbes and patient-reported disease control in mild-to-moderate UC, which could point to non-drug ways to support symptoms and microbiome health.
This work suggests that non-immune stromal cells can hold an epigenetic ‘memory’ that keeps intestinal tissue in a disease-promoting state, which may help explain relapse or incomplete responses to immune-focused...
The study points to specific immune pathways (especially Th17 differentiation) and molecular targets that might explain DSP’s anti-inflammatory effects in ulcerative colitis, which could guide further preclinical and...
Researchers used laboratory mouse and cell models to show that total glucosides of paeony (TGP) may reduce inflammation linked to ulcerative colitis and identified molecular pathways (COX‑2/arachidonic acid, NF‑κB, MAPK,...
TL1A-DR3 is implicated in both inflammation and fibrosis in IBD, so targeting it could address active disease and reduce fibrotic complications that lead to strictures. New TL1A-blocking antibodies are already in...
The study links a polyphenol-rich diet to a specific microbiome change and a microbial metabolite (4-HPAA) that reduced inflammation in mouse models — offering a possible mechanism by which diet could influence Crohn's...
This preclinical study identifies a novel peptide (spexin) and a biased signaling pathway (SPX–GALR2–Gq) that reduced colitis in mouse models, suggesting a new target and a designed peptide candidate for future IBD...
Researchers describe a natural peptide that binds IL‑17RA and reduced disease measures in mouse colitis models — a potential new mechanism for reducing gut inflammation and restoring the epithelial barrier that could...
Delays in diagnosis and restricted access to therapies can allow Crohn’s inflammation to progress, increasing the chance of bowel damage and worse outcomes. Progress on earlier detection and better matching of treatments...
These development programs could expand treatment choices for Crohn’s disease and may eventually address fibrosis and refractory disease—two major unmet needs. Progress in trials could change management options in coming...
This study describes a new oral peptide hydrogel that, in mouse models, appears to reduce colitis severity by acting on both immune signaling (TLR4) and the gut microbiome. For people with UC, treatments that target both...
New or late-stage drugs from a major company can change future treatment options and availability for people with IBD. J&J’s pipeline mentions several programs specifically targeting ulcerative colitis and Crohn’s...
Cure8 found this source from The Journal of investigative dermatology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Genetics and genomics, and Research and clinical trials....
Vitamin D deficiency was common among Albanian patients with IBD and showed a weak inverse association with disease activity in ulcerative colitis, suggesting vitamin D status may relate to symptom burden or...
Distinguishing Crohn’s disease from intestinal tuberculosis can change treatment (immune suppression versus anti‑tubercular therapy) and outcomes. This review summarizes which findings have tended to favor one diagnosis...
This trial tests whether an oral S1P modulator (etrasimod) is more effective than standard mesalazine for inducing remission in adults with active UC — a question that could affect initial treatment choices in China.
This study will collect real-world data on etrasimod, an oral S1P receptor modulator, in people with ulcerative colitis, using patient-reported symptom measures over one year — information that may help patients and...
People with Crohn's disease who develop symptomatic intestinal strictures currently often need endoscopic dilation or surgery. This trial tests an investigational oral drug (ontunisertib) aiming to improve...
A pediatric Phase 2 trial testing etrasimod could expand treatment options for children with moderately to severely active ulcerative colitis if later shown safe and effective. Families of affected children and their...
Perianal fistulas are a serious, common complication of Crohn's disease that are often difficult to heal. This study tests a real-world combination of surgery plus an approved IL-23 inhibitor (mirikizumab) to see if...
Early-phase mechanistic trials test how a new drug affects disease biology and safety; results can help decide whether larger trials should follow.
The study identifies a molecular link between epithelial mitochondrial oxidative stress and NLRP3-driven inflammation in ulcerative colitis models, suggesting a possible new target for research into disease mechanisms...
If validated, an imaging-derived adipose heterogeneity biomarker could help predict who will lose response to infliximab after induction, potentially guiding earlier treatment decisions and personalized monitoring for...
This paper explores whether individualized integrative management including traditional Chinese medicine might influence outcomes in patients with biologic‑refractory, surgery‑intended acute severe ulcerative colitis — a...
The study points to three bile-acid–related genes that may be linked to inflammation in ulcerative colitis and could serve as biomarkers or targets for future research into disease mechanisms and patient stratification.
Treg/Th17 balance is a central immune mechanism implicated in IBD pathogenesis; understanding how microbes, metabolites, and tissue context control that balance could inform new biomarkers and targeted therapies.
The study links TXNIP/NLRP3 inflammatory signaling to disease features in an animal UC model and tests engeletin and rosuvastatin as interventions that lowered inflammatory markers—information relevant to researchers...
Colon-targeted delivery systems aim to concentrate drugs in the colon, which could improve effectiveness and reduce systemic side effects for IBD and colorectal cancer treatments. Understanding these approaches helps...
This review summarizes human evidence that pesticides in the diet could affect the gut microbiome and may be linked to gastrointestinal outcomes including IBD; strongest consistent signals were for organochlorine...
The study links activation of the cGAS–STING immune-sensing pathway to NF-κB–driven inflammation and tumor formation in UC models, which could help explain mechanisms behind colitis-associated colorectal cancer risk.
The work aims to predict relapse and personalize herbal maintenance dosing for UC, which matters because better risk stratification and tailored management could reduce relapses and avoid unnecessary treatment changes.
This animal study suggests date palm pollen extract reduced inflammation and tissue damage in a rat model of colitis, which could point to new lines of research into dietary supplements or natural compounds for gut...
The study identifies a gut bacterial metabolite that appears to reduce intestinal inflammation through SIRT1 stabilization and macrophage metabolic reprogramming — a potential new biological pathway relevant to Crohn’s...
Researchers are exploring a gut microbe–derived lipid (SoL A) that may reduce inflammation relevant to IBD. If development succeeds, it could point to new, microbiome-based therapeutic approaches for people with Crohn’s...
The project aims to enable simultaneous RNA-level profiling of microbes and host cells from human biopsies, which could reveal early microbial and host gene-expression patterns linked to subclinical Crohn’s disease and...
The study links a common plant compound (oxalate) to higher stool levels and worse inflammation in IBD, suggesting diet and gut handling of oxalate could affect disease activity and that microbiome-targeted strategies...
This study reports a new herbal hydrogel designed to repair the intestinal barrier, shift gut microbes, and modulate immune signals (IL-22/IL-34) in preclinical models of ulcerative colitis—ideas that could inform future...
Adding a mesalazine retention enema to oral mesalazine improved short-term symptom relief and endoscopic signs of mucosal healing in mild-to-moderate left-sided ulcerative colitis in this retrospective study. That could...
CT-detected terminal ileitis was due to Crohn’s disease in only a small minority (12.5%) of cases in this cohort, so most patients with this imaging finding will need further testing to determine the cause.
Blood biomarkers that predict vedolizumab response could help patients and clinicians choose the most effective therapy sooner and avoid ineffective treatments. The study suggests LRG and MCP‑1 may differentiate...
If you have moderate–severe ulcerative colitis, this study suggests that typical phase III trials may exclude more than half of patients seen in specialty clinics, which can make trial results less representative of...
The paper identifies a potential microbiome–metabolite–PKC pathway by which an herbal formula reduced colonic injury in a rat model of UC; this could point to new targets for research into mucosal repair and...
People with IBD may be interested because the review summarizes biological pathways that could link gut inflammation to brain changes seen in Alzheimer’s disease, suggesting possible shared mechanisms and future research...
Comparative real-world data may help patients and clinicians weigh expected benefits and risks of risankizumab versus ustekinumab in Crohn’s disease, including effects on steroid-free remission and fistula healing.
People with ulcerative colitis may be interested because the study describes a natural compound that reduced inflammation and disease signs in a mouse model and acted through the gut microbiota and immune pathways —...
